Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib

被引：30
|
作者：
Fukuda, Naoki [1 ]
Wang, Xiaofei [1 ]
Ohmoto, Akihiro [1 ]
Urasaki, Tetsuya [1 ]
Sato, Yasuyoshi [1 ]
Nakano, Kenji [1 ]
Nishizawa, Masatoshi [1 ]
Yunokawa, Mayu [1 ]
Ono, Makiko [1 ]
Tomomatsu, Junichi [1 ]
Takahashi, Shunji [1 ]
机构：
[1] JFCR, Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
来源：
IN VIVO | 2020年 / 34卷 / 02期
基金：
日本学术振兴会;
关键词：
Thyroid cancer; lenvatinib; neutrophil-to-lymphocyte ratio; prognostic factors; ANTITUMOR ACTIVITIES; INHIBITOR; E7080; CARCINOMA; IMPACT;
D O I：
10.21873/invivo.11828
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Background/Aim: Neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR-DTC). Little is known whether NLR can be a tumor marker for RR-DTC patients treated with lenvatinib. Patients and Methods: We retrospectively analyzed RR-DTC patients treated with lenvatinib. NLR was calculated at 4 points before and during lenvatinib treatment. Results: The median NLR value increased at the start of lenvatinib treatment, compared to 6 months prior to initiation of lenvatinib treatment. The median overall survival was significantly longer in patients with the lower NLR (<3) at the start of lenvatinib treatment. The median NLR values decreased when the patients achieved best tumor response, and increased again upon disease progression. Conclusion: NLR values vary before and during lenvatinib treatment, suggesting that this ratio can reflect disease activity of RR-DTC. NLR can supportively be used as a tumor marker of RR-DTC and an indicator for starting lenvatinib treatment.
引用
收藏
页码：709 / 714
页数：6
相关论文
共 50 条
  • [41] Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy
    Banna, G. L.
    Di Quattro, R.
    Malatino, L.
    Fornarini, G.
    Addeo, A.
    Maruzzo, M.
    Urzia, V
    Rundo, F.
    Lipari, H.
    De Giorgi, U.
    Basso, U.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (11): : 2130 - 2135
  • [42] Neutrophil-to-lymphocyte ratio dynamics predict for survival in lung cancer treated with SBRT
    Chowdhary, M.
    Dhawan, R.
    Switchenko, J.
    Tian, S.
    King, K.
    Batus, M.
    Fidler, M.
    Bonomi, P.
    Sen, N.
    Patel, K.
    Khan, M.
    Gaurav, M.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S400 - S401
  • [43] Longitudinal measurements of neutrophil-to-lymphocyte ratio in nasopharyngeal cancer treated with concurrent chemoradiotherapy
    Muangwong, Pooriwat
    Homkham, Nontiya
    Narueban, Wattanapong
    Tadadoltip, Chin
    Jongjumnien, Chayaporn
    Taenawakun, Nuttida
    Teerapattanaphong, Jutamas
    Chitapanarux, Imjai
    PLOS ONE, 2023, 18 (10):
  • [44] Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy
    G. L. Banna
    R. Di Quattro
    L. Malatino
    G. Fornarini
    A. Addeo
    M. Maruzzo
    V. Urzia
    F. Rundo
    H. Lipari
    U. De Giorgi
    U. Basso
    Clinical and Translational Oncology, 2020, 22 : 2130 - 2135
  • [45] The Time Series Behavior of Neutrophil-to-Lymphocyte Ratio in Thyroid Cancer Patients on Tyrosine Kinase Inhibitor Therapy
    Tomoda, Chisato
    Sugino, Kiminori
    Kitagawa, Wataru
    Nagahama, Mitsuji
    Ito, Koichi
    ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY, 2021, 83 (05): : 347 - 353
  • [46] Neutrophil-to-Lymphocyte Ratio in Renal Transplant Patients
    Ohtaka, Mari
    Kawahara, Takashi
    Takamoto, Daiji
    Mochizuki, Taku
    Ishida, Hiroaki
    Hattori, Yusuke
    Makiyama, Kazuhide
    Yao, Masahiro
    Teranishi, Jun-ichi
    Uemura, Hiroji
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2018, 16 (05) : 546 - 549
  • [47] Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: A meta-analysis
    Li, Li-Li
    Pan, Li-Sha
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2023, 39 (08): : 842 - 852
  • [48] Neutrophil-to-lymphocyte ratio as a prognostic predictor for patients with cancer treated with stereotactic body radiation therapy: A meta-analysis
    Yu, Yipin
    Tan, Duoting
    Liao, Can
    Yang, Pei
    Hu, Zhixi
    Liang, Hao
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (05)
  • [49] Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy
    Mihai Dorin Vartolomei
    Romain Mathieu
    Vitaly Margulis
    Jose A. Karam
    Morgan Rouprêt
    Ilaria Lucca
    Aurélie Mbeutcha
    Christian Seitz
    Pierre I. Karakiewicz
    Harun Fajkovic
    Christopher G. Wood
    Alon Z. Weizer
    Jay D. Raman
    Nathalie Rioux-Leclercq
    Andrea Haitel
    Karim Bensalah
    Michael Rink
    Alberto Briganti
    Evanguelos Xylinas
    Shahrokh F. Shariat
    World Journal of Urology, 2017, 35 : 121 - 130
  • [50] The prognostic value of derived neutrophil-to-lymphocyte ratio in patients treated with checkpoint inhibitors
    Mullally, W. J.
    Greene, J. P.
    Cahill, T.
    Ryan, M. B.
    Horgan, A.
    Jordan, E. J.
    O'Connor, M.
    Calvert, P. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S716 - S717
12345